Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anti-Viral Technologies, LLC is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is being reviewed by 1 distinct examiner, COHEN, MICHAEL P, who is also identified as the busiest examiner for the portfolio. Consequently, COHEN, MICHAEL P is responsible for 1 busiest examiner pending action, which represents the company's entire current prosecution workload.
The prosecution of this portfolio is limited to 1 distinct art unit, suggesting a narrow technical focus for the company's biotechnology innovations. With only 1 pending office action and 1 distinct examiner, the administrative and strategic requirements are highly concentrated. Practitioners can focus their efforts on a single point of contact and a single set of art unit standards to optimize the outcome.
The involvement of 1 distinct examiner means that the outcome of the current prosecution is tied to the review of COHEN, MICHAEL P. The presence of 1 distinct art unit further simplifies the technical context for the application. Managing 1 pending office action involves a direct and focused interaction with the patent office, allowing for a specialized response that addresses the specific requirements of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 1 | 58.9% | +27.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19326649 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF SYNTHETIC LYSINE ANALOGS AND MIMETICS | COHEN, MICHAEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19326649 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF SYNTHETIC LYSINE ANALOGS AND MIMETICS | COHEN, MICHAEL P | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19326649 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF SYNTHETIC LYSINE ANALOGS AND MIMETICS | COHEN, MICHAEL P | 1612 | §103§112 | Non-Final OA | — | Pending | Sep 11, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnti-Viral Technologies, LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael P Cohen has the most, with 1 of Anti-Viral Technologies, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
